Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Immunocore Hldgs Q2 2024 GAAP EPS $(0.23) Beats $(0.45) Estimate, Sales $75.400M Beat $74.580M Estimate

Author: Benzinga Newsdesk | August 08, 2024 07:25am
Immunocore Hldgs (NASDAQ:IMCR) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.45) by 48.89 percent. The company reported quarterly sales of $75.400 million which beat the analyst consensus estimate of $74.580 million by 1.10 percent. This is a 24.21 percent increase over sales of $60.704 million the same period last year.

Posted In: IMCR


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist